Eyebright Medical Technology (Beijing) Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Eyebright Medical Technology (Beijing) Co., Ltd. carries a market capitalization of 7.59B, placing it among publicly traded companies globally. Its enterprise value stands at 13.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.59B |
| Enterprise Value | 13.01B |
Share Statistics
Eyebright Medical Technology (Beijing) Co., Ltd. currently has 193.14M shares outstanding.
| Shares Outstanding | 193.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Eyebright Medical Technology (Beijing) Co., Ltd. trades at a trailing price-to-earnings ratio of 33.04. The price-to-sales ratio is 8.61, and the price-to-book ratio stands at 10.05.
| PE Ratio | 33.04 |
| PS Ratio | 8.61 |
| PB Ratio | 10.05 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | 69.11 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Eyebright Medical Technology (Beijing) Co., Ltd. trades at an EV/EBITDA multiple of 27.61 and an EV/FCF ratio of 62.06. The EV/Sales ratio of 8.61 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.61 provides insight into valuation relative to core operating earnings.
| EV / Sales | 8.61 |
| EV / EBITDA | 27.61 |
| EV / EBIT | 27.61 |
| EV / FCF | 62.06 |
Financial Position
Eyebright Medical Technology (Beijing) Co., Ltd. maintains a current ratio of 3.82, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.68, indicating elevated leverage, while an interest coverage ratio of 19.89 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.82 |
| Quick Ratio | 1.87 |
| Debt / Equity | 19.68 |
| Debt / EBITDA | 1.25 |
| Interest Coverage | 19.89 |
Financial Efficiency
Eyebright Medical Technology (Beijing) Co., Ltd. posts a return on equity of 34.43 and a return on invested capital of 12.64.
| Return on Equity (ROE) | 34.43 |
| Return on Assets (ROA) | 10.70 |
| Return on Invested Capital (ROIC) | 12.64 |
| Return on Capital Employed (ROCE) | 20.51 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.13 |
Taxes
Over the trailing twelve months, Eyebright Medical Technology (Beijing) Co., Ltd. has paid 41.31M in income taxes, reflecting an effective tax rate of 9.47.
| Income Tax | 41.31M |
| Effective Tax Rate | 9.47 |
Stock Price Statistics
Eyebright Medical Technology (Beijing) Co., Ltd.'s stock has declined approximately -42.3303% over the past 52 weeks. The 50-day moving average sits at 44.35, while the 200-day moving average is 57.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | -42.3303% |
| 50-Day Moving Average | 44.35 |
| 200-Day Moving Average | 57.09 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Eyebright Medical Technology (Beijing) Co., Ltd. generated 1.51B in revenue and converted that into 393.67M in net income, yielding earnings per share of 2.09. EBITDA reached 471.16M, while operating income came in at 471.16M.
| Revenue | 1.51B |
| Gross Profit | 969.36M |
| Operating Income | 471.16M |
| Pretax Income | 436.10M |
| Net Income | 393.67M |
| EBITDA | 471.16M |
| EBIT | 471.16M |
| Earnings Per Share (EPS) | 2.09 |
Balance Sheet
Eyebright Medical Technology (Beijing) Co., Ltd. holds 800.55M in cash and equivalents against 591.08M in total debt, resulting in a net debt position of -232.54M. Total book value stands at 1.29B, with working capital of 1.21B providing operational flexibility.
| Cash & Cash Equivalents | 800.55M |
| Total Debt | 591.08M |
| Net Debt | -232.54M |
| Equity (Book Value) | 1.29B |
| Book Value Per Share | 6.85 |
| Working Capital | 1.21B |
Cash Flow
After subtracting -188.19M in capital expenditures, free cash flow totaled -188.19M - equivalent to -1.00 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -188.19M |
| Free Cash Flow | -188.19M |
| FCF Per Share | -1.00 |
Margins
Eyebright Medical Technology (Beijing) Co., Ltd. operates with a gross margin of 64.15, reflecting its pricing power and cost economics. The operating margin of 31.18 and net profit margin of 26.05 provide insight into operational efficiency.
| Gross Margin | 64.15 |
| Operating Margin | 31.18 |
| Pretax Margin | 28.86 |
| Profit Margin | 26.05 |
| EBITDA Margin | 31.18 |
Dividends & Yields
The company's payout ratio of 5.41 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.11 |
| Dividend Yield | N/A |
| Payout Ratio | 5.41 |
| Shareholder Yield | -0.37 |
| FCF Yield | 1.45 |
Stock Splits
Eyebright Medical Technology (Beijing) Co., Ltd.'s most recent stock split took place on June 5, 2024 with a 5:9 split ratio.
| Last Split Date | 6/5/2024 |
| Split Ratio | 5:9 |
Scores
Eyebright Medical Technology (Beijing) Co., Ltd. posts an Altman Z-Score of 10.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.15 |